Repligen Stock Price, News & Analysis

Repligen (NASDAQ:RGEN) has launched the CTech™ SoloVPE® PLUS System, an advanced UV-based Variable Pathlength Technology system for biopharmaceutical manufacturers. This next-generation system delivers precise concentration measurements in under 30 seconds without requiring dilution or background correction.

The system addresses the bioprocess industry's shift toward higher drug concentration formulations, offering key advantages including: 70% reduction in process steps, doubled data collection speed, measurement capability for mAbs from 0.01 mg/mL to 320 mg/mL with R²≥ 0.999, and elimination of dilution requirements. Applications include protein concentration measurement, nucleic acids quantitation, and mRNA measurement in therapeutics.

The system integrates with CTech™ ViPER® ANLYTX Software, featuring SQL data storage and OPC-UA communication for real-time access and scalable operations. This launch marks the first of several planned product releases for 2025.

BioLife Solutions (BLFS) has appointed Tony J. Hunt, Executive Chairman of Repligen , to its board of directors effective January 2, 2025, expanding the board to six members. Hunt brings extensive experience in bioprocessing innovation and leadership, having served as Repligen's CEO for nine years before becoming Executive Chairman in September 2024. His prior roles include President of Bioproduction at Life Technologies and Senior Director of Pharma Programs at Applied Biosystems. BioLife Solutions, a leading supplier of cell processing tools for the cell and gene therapy market, aims to leverage Hunt's expertise to strengthen its position in CGT bioprocessing solutions.

Repligen (NASDAQ:RGEN) has published its 2023 Corporate Sustainability Report, titled 'Advancing Impacts.' The report outlines progress across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities, and Partnerships & Pathways.

Key achievements include:

• Expansion of 100% renewable electricity to 13 of 18 manufacturing sites (88% of global consumption)
• Increase in women in management positions from 27% to 29%
• 68% reduction in Scope 2 emissions from 2022 to 2023
• 60% increase in productivity savings through Repligen Performance System
• Commitment to net-zero emissions by 2050 with Science Based Targets initiative

The report aligns with major reporting frameworks including GRI Standards, SASB, UN SDGs, and TCFD, and serves as Repligen's 2023 Communication on Progress for the UN Global Compact.

Repligen (NASDAQ:RGEN) has launched AVIPure® dsRNA Clear OPUS® columns, a new solution for purifying mRNA therapeutics and vaccines. The product combines Repligen's dsRNA purification resin with pre-packed OPUS columns, offering superior removal of double-stranded RNA impurities from transcribed RNA.

The technology achieves a 2-3 log reduction of dsRNA impurities in one minute of residence time in flow through mode, without requiring heat or solvents. This launch follows Repligen's recent acquisition of Tantti Laboratory Inc., integrating Tantti's DuloCore® bead technology with AVIPure affinity ligands.

The solution aims to address growing market demands for efficient dsRNA removal in mRNA-based biologics, ensuring drug efficacy while preventing undesirable immune responses.

Repligen (RGEN) reported Q3 2024 financial results with revenue of $155 million, up 10% year-over-year. CDMO and equipment revenues grew approximately 20% and 6% respectively. The company achieved record quarterly revenue for new modalities, increasing 20% year-over-year. Full-year 2024 revenue guidance was narrowed to $630-$639 million. Q3 adjusted earnings per share was $0.43, compared to $0.23 in Q3 2023. The company announced plans to acquire Tantti Laboratory to support its Proteins and Chromatography franchises.

Repligen (NASDAQ:RGEN) has announced its participation in three major investor conferences in November 2024. The company will present at the UBS Global Healthcare Conference in Rancho Palos Verdes on November 14, the Stifel Healthcare Conference in New York City on November 19, and the Stephens Annual Investment Conference in Nashville on November 20.

CFO Jason Garland and CEO Olivier Loeillot will participate in analyst-led discussions at these events. All presentations will be available via live webcast through Repligen's Investor Relations website, with -time replay access after the events.

Repligen (NASDAQ:RGEN) has scheduled its third quarter 2024 financial results announcement for Tuesday, November 12, 2024, before market open, followed by a conference call at 8:30 a.m. ET. CEO Olivier Loeillot mentioned that the team is working to complete previously disclosed revenue restatements from September 18. The company plans to file amended periodic reports along with the Q3 2024 results. The conference call will be accessible via toll-free numbers and webcast through the company's Investor Relations section, with replay options available using passcode 3384562.

Repligen (NASDAQ:RGEN) has announced the grand opening of its Repligen Training & Innovation Center (RTIC) at its Waltham headquarters. The 7,500 square foot facility is designed to provide customers with pre- and post-sales support and hands-on experience with Repligen's bioprocessing solutions. The RTIC features product exhibits, demonstration areas, and technical training space, showcasing Repligen's complete collection of bioprocessing technologies.

The center includes displays of upstream intensification technologies, downstream products, and integrated systems. It also highlights process analytics technologies and fluid management products. The RTIC aims to elevate customer experience through live engagement with subject matter experts and demonstrate Repligen's end-to-end capabilities.

In addition to the RTIC, Repligen has expanded its Waltham site to a total of 182,000 square feet and completed a site relocation and expansion in Jüri, Estonia, earlier this year. The Estonian facility is an 80,000 square foot, LEED Silver certified Customer Center of Excellence for advanced TFF and chromatography systems.

Repligen (NASDAQ:RGEN), a leading bioprocessing technology company in the life sciences sector, has announced its participation in the upcoming Wells Fargo Healthcare Conference. The event is scheduled to take place from September 4-6 in Boston.

Olivier Loeillot, Repligen's President and CEO, will engage in an analyst-led discussion on Friday, September 6, at 8:45 a.m. ET. Investors and interested parties can access a live webcast of the presentation through Repligen's Investor Relations website at www.repligen.com. The replay of the presentation will be available for a time after the event.

This conference provides Repligen with an opportunity to showcase its latest developments and strategic initiatives in the bioprocessing technology field to investors and industry analysts.